Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 26.9× earnings vs its 50.0× historical median P/E.
Fair value ≈ $1261 · price $678.51 today
Undervalued · 46% below
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$SANA $ELDN $LCTX $LZAGF Medical University initiative aims to integrate 3-liter bioreactors into a closed-loop GMP manufacturing unit to provide personalized, automated cell therapies for Type 1 Diabetes.
The industry needs to overcome this problem, good to see progress.
https://www.youtube.com/watch?v=LLTadaoFci0
@Arb_raccoon I can see a hostile bid at $2.
A tender offer could happen at any time, simply because the cash and debt position 😉 are too difficult to ignore.
I also can see $TMO or $LZAGF or even $DHR making a bid without it making a dent in their share price.
Anyone buying this out at $3.X or less is "stealing" it, in my opinion.
$MXCT So this appears to be trading around below anticipated 2028 cash on hand.
The EV is considerably negative, and the company theoretically has enough cash to buy back all outstanding shares (assuming doing so wouldn't begin running up the price).
We are down around 30% in a month, with the share price setting new all-time lows.
Management is silent.
The company appears to be more valuable in a liquidation than it does if they continue operating.
Perhaps a take-private option should be considered, given that they have completely failed as a public company thus far.
Book value appears to be around the 1.70s...
I could see $TMO $DHR or maybe $LZAGF absorbing them for around 2-3 per share without even feeling the expense.
Otherwise, we need some exellent news from management asap.
$CDXS $LZAGF $PFIZER.NSE
They do have a preexisting relationship. https://www.epa.gov/greenchemistry/presidential-green-chemistry-challenge-2006-greener-reaction-conditions-award
$ILMN $LZAGF Illumina enters licensing agreement with Lonza
Synaffix B.V., a Lonza (LZAGY) company, announced it has entered into a licensing agreement with Illumina (ILMN). The agreement grants Illumina access to Synaffix's patented metal-free click chemistry technology. Synaffix's patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing products.
$LZAGF HUGE ALS PARTNERSHIP WITH $NRSN
#CureALS $NRSN presenting POSITVE DATA SOON!!
Gave you MOFO's $VKTX at $8.00 (10X BANGER)
$AXSM was 10X PLUS BANGER
$NRSN LOAD ZONE HERE
$LZAGF
High Tide Reports Third Consecutive Quarter
of Record Revenue and Adjusted EBITDA
of $118.1 Million and $6.6 Million, Respectively!
HITI (ASK @ 1.35)
HITI.VN (ASK @ 1.75)
13th Straight Quarter of Positive Adjusted EBITDA, Representing a 174% Increase Year-Over-Year and 20% Sequentially, Driven by Significant Cost Reductions in General and Administrative Expenses
High Tide Reaches 9.5% of Canadian Cannabis Retail Market Share Outside of Quebec1, Up From 9% in the Previous Quarter
PR here : https://finance.yahoo.com/news/high-tide-reports-third-consecutive-200100953.html
$LZAGF - Hold Lonza and IDEXX Laboratories ( $IDXX ) in the same portfolio. https://www.macroaxis.com/invest/pair-correlation/LZAGF/IDXX/Lonza-vs-IDEXX #portfolio_prospective #better_portfolio #diversify
$LZAGF
Impressive! : Cannara Biotech Inc.
Reports Record Q4 and 2022 Fiscal Year Financial Results
LOVFF (ASK @ 0.0795)
LOVE.VN (ASK @ 0.10)
PR is long to read but wow!! (And still under the radar!)
Company recorded a record high of $12 million in quarterly revenue (84% YoY increase) and Net Income of $2.6 million!
Full year revenues were $36 million, a 108% increase!
Delivered its sixth consecutive quarter
of positive Adjusted EBITDA of $2.5M, and $5.3M for fiscal year 2022.
.lzagf
$LZAGF
CNVCF (ASK @ 0.30)
BHSC.CN (ASK @ 0.365)
Bioharvest Sciences Inc.
Successfully Completes Cannabis R&D Program :
First company ever to announce that it could
produce Cannabis biomass without growing the plant itself!
Bioharvest has now produced Cannabis
in large scale industrial bioreactors,
marking the start of the transition
to commercial scale manufacturing.
More in PRelease!
.t
